XORTX Receives Nasdaq Notification on Minimum Bid Price Deficiency

XORTX Therapeutics Inc. announced that it has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The company's common shares have been trading below the required $1.00 per share for 30 consecutive business days. XORTX has 180 calendar days to regain compliance, during which its shares will continue to trade on the Nasdaq Capital Market. The company is evaluating options to resolve the deficiency and remains listed on the TSX Venture Exchange. XORTX is focused on developing therapies for kidney disease and gout, with several products in clinical and pre-clinical stages.